Advertisement

Topics

FDA grants Roche’s Alecensa Priority Review for initial treatment of people with ALK-positive lung cancer

01:00 EDT 3 Aug 2017 | Hoffmann-La Roche Ltd

Roche announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and granted Priority Review for Alecensa® (alectinib) as an initial (first-line) treatment for people with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Original Article: FDA grants Roche’s Alecensa Priority Review for initial treatment of people with ALK-positive lung cancer

NEXT ARTICLE

More From BioPortfolio on "FDA grants Roche’s Alecensa Priority Review for initial treatment of people with ALK-positive lung cancer"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...